What Vastinan Treats — Main Uses and Benefits

Vastinan is generally used across therapeutic domains that involve symptoms related to physical discomfort and symptoms that interfere with daily functioning experienced in stable angina pectoris. The medicine is applied in addressing conditions characterized by periods of heightened symptoms where additional symptomatic support is needed. Vastinan is commonly used for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled by or intolerant to first-line antianginal therapies. It may assist with managing symptoms that become more disruptive during flare-ups and provides support that helps ease the overall symptom burden.

---

The therapy is commonly used to help with managing symptoms that create noticeable physiological strain related to physical exertion. This functional support assists with maintaining functional stability when symptoms are more noticeable during activity. The medicine is considered relevant for managing symptoms linked to organ-specific functional stress in specific clinical contexts, such as in patients with conditions associated with acute or disruptive episodes and those with comorbidities like diabetes mellitus.

---

“The primary goal of this symptomatic support is to help patients cope more steadily with symptom fluctuations and maintain a sense of stability when symptoms are more noticeable.”

---

Quick Fact: Relief for Exertion-Related Symptoms The medicine is commonly used to help with managing symptoms that create noticeable physiological strain related to physical activity, which assists with maintaining functional stability.

Regulatory References

1. Trimetazidine European Commission Indication Document

This section outlines the official eligibility and non-eligibility criteria for Vastinan (Trimetazidine), as established by regulatory bodies.

Populations Who Must Not Use Vastinan (Contraindications)

Contraindication	Details
Movement Disorders	Patients with Parkinson disease, parkinsonian symptoms, tremors, restless leg syndrome, or other related movement disorders.
Renal Function	Patients with severe renal impairment (creatinine clearance < 30 mL/min).
Hypersensitivity	Documented hypersensitivity to the active substance or any other component.

Use Limitations and Special Populations

Age and Development:

• Children and Adolescents (under 18 years): Use is not recommended as safety and efficacy have not been established in this age group.
• Elderly Patients (over 75 years): Caution is required, and a dose adjustment must be considered due to the age-related decrease in renal function.

Organ Impairment:

• Moderate Renal Impairment (creatinine clearance 30-60 mL/min): Requires specific dose reduction and special caution.

Physiological States:

• Pregnancy: It is preferable to avoid use as a precautionary measure due to no or limited human data.
• Breastfeeding: The medicine should not be used because the risk to the newborn/infant cannot be excluded.

Interactions with other medicines and products

Vastinan (Trimetazidine) is generally considered to have a low potential for complex drug-drug interactions based on its pharmacological profile. Authoritative regulatory information indicates that the drug's metabolism and elimination pathways minimize the risk of interactions via common enzyme systems.

Pharmacokinetic Interaction Profile

Regulatory assessments confirm that Vastinan is not significantly metabolized by major Cytochrome P450 (CYP) enzyme systems and is primarily eliminated by the kidneys in an unchanged form. Consequently, co-administration with inhibitors or inducers of common enzymes like CYP3A4, CYP2D6, or P-glycoprotein is not expected to result in clinically relevant changes to Vastinan's concentration or the concentration of the co-administered drug.

Pharmacodynamic and Clearance-Related Constraints

The most significant interaction considerations are related to physiological clearance and pharmacodynamic effects, rather than drug-drug interactions.

• Movement Disorders: Vastinan carries an inherent pharmacodynamic risk of causing or worsening symptoms such as tremor, rigidity, and gait disturbance. This requires close monitoring, particularly in patients with existing motor or neurological conditions.
• Renal Function: The drug's reliance on renal elimination establishes a critical interaction-related constraint: use is prohibited in individuals with severe renal impairment (creatinine clearance less than 30 mL/min). A lower dose is specified for moderate renal impairment, reflecting a required adjustment based on altered clearance.

Shifting the Heart's Energy Source

Vastinan's primary mechanism is the selective inhibition of 3-ketoacyl CoA thiolase (3-KAT), a key mitochondrial enzyme in fatty acid oxidation ( FAO) . Inhibition of FAO secondarily promotes the use of glucose oxidation ( GO), shifting the heart muscle's fuel substrate toward GO. This action modulates the cell's energy-generating process.

---

Promoting Cellular Resilience

The metabolic shift toward GO results in cardiac metabolic efficiency. The GO pathway, in comparison to FAO, yields a higher ATP (cellular energy) per unit of oxygen consumed. This sustained energy reserve contributes to the maintenance of cellular homeostasis by ensuring ion pumps and regulatory systems remain functional. This mechanistic domain supports the maintenance of the cell's functional integrity.

How Vastinan is Used: Official Administration Guidelines

Vastinan (Trimetazidine Dihydrochloride) is a prescription medicine used as an add-on symptomatic therapy for stable angina pectoris. Its use is defined by guidelines focusing on the proper administration protocol.

Standard Administration and Dosing

Vastinan is administered via the oral route as a 35 mg modified-release (MR) film-coated tablet. The standard usage pattern is determined by dosing recommendations:

• Dose: One 35 mg tablet.
• Frequency: Twice daily (once in the morning and once in the evening).
• Maximum Daily Dose: 70 mg total per day.

Important Administration Instructions:

The modified-release tablet must be swallowed whole and should not be crushed or chewed. The medicine should always be taken during meals (e.g., breakfast and dinner) to support proper absorption and stable drug delivery.

Use Patterns and Adjustments

The benefit of Vastinan treatment should be formally assessed after three months of use. If there is no satisfactory response or benefit observed within this period, it is recommended that the medicine be discontinued.

Population Group	Official Dosing Instruction
Moderate Renal Impairment (CrCl 30-60 mL/min)	One 35 mg tablet once daily (taken in the morning during breakfast)
Severe Renal Impairment (CrCl < 30 mL/min)	Contraindicated/Not recommended
Pediatric (Under 18)	Not recommended; safety and efficacy not established

For elderly patients, caution is advised during dose titration due to potential age-related decrease in kidney function.

Vastinan: Recent Clinical Evidence

The evidence base for Vastinan relies heavily on short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time when the medicine was evaluated as an add-on to standard first-line antianginal medications for stable angina. The research examined outcomes related to physical discomfort and daily functioning.

Symptomatic and Functional Study Findings

Studies monitored how symptoms evolved over short periods (typically 4–12 weeks), evaluating the frequency of angina attacks and the amount of rescue medication used. Research also explored changes in functional capacity, such as the total exercise time recorded during standardized stress tests. However, research exploring short-term changes in these functional measures sometimes reported mixed findings across different evidence reviews.

Evidence Gaps and Long-Term Data

A key limitation is that the primary efficacy trials were short-term. Long-term effects are not fully established, and long-term outcomes on major cardiovascular events (MACEs) are not well characterized by current evidence. Certainty remains low regarding whether Vastinan was associated with a reduction in MACEs over extended periods.

Subgroup Research

Vastinan was also evaluated in studies focusing on specific subgroups, including older adults and patients with comorbidities such as diabetes mellitus. Although patterns of measured outcomes were observed in some studies involving diabetes, data for certain high-risk groups remain insufficient. Data show patterns related to its use as an add-on therapy; therefore, research has not fully established its use as a first-line treatment.

Key Studies & References

1. Trimetazidine: Scientific Discussion and Indication Document (European Commission)
2. Trimetazidine Drug Information (MedlinePlus)

Common questions about Vastinan (FAQ)

Q: What is the main medical use of Vastinan as listed in the official documents?

According to official regulatory documents, this medicine is indicated as an add-on treatment for the symptomatic management of stable angina pectoris in adults. It is intended for use when standard first-line therapies are either not working effectively or cannot be tolerated by the patient.

Q: Is Vastinan a brand name or a generic name for the active ingredient?

Vastinan is the brand name used for the medicine. The active substance within the tablet is Trimetazidine Dihydrochloride, which is the official generic name. You may encounter this substance under several different trade names.

Q: What are the differences between how Vastinan works and how older medicines work?

Vastinan is classified as a metabolic agent that works by shifting the heart’s energy source toward glucose oxidation, which uses oxygen more efficiently. This mechanism is distinct from many traditional anti-anginal medicines that primarily work by affecting blood flow or heart rate.

Q: Do the common side effects of Vastinan lessen or go away after continued use?

According to official product information, common side effects—such as nausea or abdominal discomfort—are usually mild to moderate. These effects may lessen or subside as the body adjusts to the new medicine. If any side effects persist or become bothersome, a healthcare professional should be consulted.

Q: Can Vastinan interact with common over-the-counter pain relievers?

Official regulatory assessments indicate that the medicine has a low potential for complex drug-drug interactions with other medicines. Despite this, when considering any new over-the-counter pain relievers while taking this medication, it is important to consult a healthcare professional.

Q: Is it safe to drink alcohol while using Vastinan?

Official patient information does not state whether it is safe to consume alcohol while using this medicine. Therefore, consultation with a healthcare professional is recommended regarding alcohol consumption during treatment.

Q: Does Vastinan typically cause changes in mood or sleep patterns?

Official reports of side effects include sleep disorders, such as feeling drowsy or having difficulty sleeping. Additionally, psychiatric symptoms, like mood swings or feelings of depression, have also been reported, although they are noted as less common.

Q: What is the significance of the different doses or strengths of Vastinan?

The medicine is available in different strengths and formulations, such as 20 mg and 35 mg modified-release tablets. These different options are used to allow for varying dosing schedules or for necessary dose adjustments required based on the patient’s kidney function.

Q: What should be done if a dose of Vastinan is accidentally missed?

If a dose is accidentally forgotten, official patient information generally advises skipping the forgotten dose and resuming the normal treatment schedule. It is noted that patients should not take a double dose to compensate for the missed one.

Q: What kind of monitoring is officially recommended for patients taking Vastinan?

Regulatory guidelines advise that healthcare professionals should regularly check for movement disorders, such as tremors or problems with walking, especially in older adults. Furthermore, the official documents state that the therapeutic benefit of the treatment must be formally evaluated after three months of use.

Q: Is Vastinan meant for long-term treatment, or is it usually temporary?

The medicine is generally prescribed for long-term use as an add-on therapy for stable angina pectoris. However, official guidelines require that a healthcare professional formally assess the therapeutic benefit of the medicine after three months of continuous use.

Q: What are the official guidelines for stopping the use of Vastinan?

Official guidelines state that the medicine should be discontinued if a satisfactory therapeutic response is not achieved after three months of treatment. Regulatory information also requires definitive withdrawal of the medicine if the patient develops movement disorders while using the drug.

Q: Is Vastinan approved by regulatory bodies like the FDA or EMA?

The medicine has been reviewed and approved by the European Medicines Agency (EMA) for use as an add-on treatment for stable angina pectoris. This status confirms its official designation as a prescription medicine in the European Union.

Q: Can patients with pre-existing heart conditions use Vastinan?

The medicine is indicated for use by adults with stable angina pectoris, a type of heart condition. However, official documents list strict contraindications related to movement disorders, severe kidney impairment, and hypersensitivity.

Q: Is there a generic alternative to Vastinan available on the market?

The active substance, Trimetazidine Dihydrochloride, is used in many authorized medicines globally. Official information indicates this active substance is available under numerous different trade names. This indicates that the active substance is available under multiple authorized products.

Q: Does Vastinan affect blood test results?

Rare, serious adverse reactions reported in official documents include changes to the blood that can be detected during routine blood tests. These include elevated liver enzymes and a severe reduction in the number of white blood cells or blood platelets.

Q: What does the official patient information say about the risk of dependence with Vastinan?

Official patient information notes that this medicine is not considered to be habit-forming.

Q: Does having a history of mental health conditions affect eligibility for Vastinan?

Official contraindications for use are focused on movement disorders, severe kidney impairment, and hypersensitivity, and do not include general mental health conditions. However, the regulatory documentation does list sleep disorders and psychiatric symptoms as reported side effects.

Q: What is the expected timeline for a patient to achieve maximum benefit from Vastinan?

The medicine is designed to maintain a continuous, stable concentration of the active substance over time. For this reason, official guidelines state that a healthcare professional should formally assess the treatment’s therapeutic benefit after three months of use.

Official Regulatory Storage and Disposal Requirements

This section summarizes the official storage, handling, and disposal instructions for Vastinan as specified in regulatory documents, ensuring compliance with stability and safety standards.

Storage and Protection	Requirement
Temperature	Store below a specified maximum temperature (e.g., 25 C or 30 C) in a cool, dry area.
Environmental Protection	The medicine must be kept in its original packaging to protect it from direct light and moisture. Do not freeze the product.
Child-Safety	It is an official requirement to keep Vastinan out of the sight and reach of children at all times.

Disposal Protocol

To dispose of expired or unused Vastinan, follow local pharmaceutical take-back programs or consult a pharmacist for guidance on safe disposal. Unless specifically instructed by regulatory labeling, the medicine should not be flushed down a toilet or poured down a drain to prevent environmental contamination.